High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker

Kei Hiraoka, Yasuhiro Hida, Masaki Miyamoto, Taro Oshikiri, Masato Suzuoki, Yoshihiro Nakakubo, Toshiya Shinohara, Tomoo Itoh, Toshiaki Shichinohe, Satoshi Kondo, Noriyuki Kasahara, Hiroyuki Katoh

Research output: Contribution to journalArticle

57 Citations (Scopus)

Abstract

RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a recently identified human tumor-associated antigen expressed on various cancer cells. It is thought that tumor cells evade immune surveillance by expression of RCAS1, which induces apoptotic cell death in receptor-positive immune cells. The purpose of our study was to investigate the relation between RCAS1 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma. Immunohistochemical analysis for RCAS1 was performed on paraffin-embedded specimens of 80 patients (mean age, 62 years) who underwent surgical resection for pancreatic adenocarcinoma. Of the 80 specimens, 77 (96%) were positive for RCAS1. No significant correlation was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). RCAS1 expression was very frequently observed and the survival of patients with high RCAS1 expression was significantly shorter than that of those with low expression (p = 0.0012). Multivariate analysis using the Cox regression model indicated that high RCAS1 expression was an independent prognostic factor (risk ratio, 3.090; p = 0.0090). These results suggested that RCAS1 might be a significant tumor marker for pancreatic adeno-carcinoma and an unfavorable predictor for prognosis of patients who have undergone surgical resection.

Original languageEnglish (US)
Pages (from-to)418-423
Number of pages6
JournalInternational Journal of Cancer
Volume99
Issue number3
DOIs
StatePublished - May 20 2002
Externally publishedYes

Fingerprint

Neoplasm Antigens
Adenocarcinoma
Neoplasms
Death Domain Receptors
Tumor Biomarkers
Proportional Hazards Models
Paraffin
Cell Death
Multivariate Analysis
Lymph Nodes
Odds Ratio
Neoplasm Metastasis
Antigens
Survival

Keywords

  • Immunohistochemical analysis
  • Pancreatic carcinoma
  • Prognostic factor
  • RCAS1
  • Tumor-associated antigen

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. / Hiraoka, Kei; Hida, Yasuhiro; Miyamoto, Masaki; Oshikiri, Taro; Suzuoki, Masato; Nakakubo, Yoshihiro; Shinohara, Toshiya; Itoh, Tomoo; Shichinohe, Toshiaki; Kondo, Satoshi; Kasahara, Noriyuki; Katoh, Hiroyuki.

In: International Journal of Cancer, Vol. 99, No. 3, 20.05.2002, p. 418-423.

Research output: Contribution to journalArticle

Hiraoka, K, Hida, Y, Miyamoto, M, Oshikiri, T, Suzuoki, M, Nakakubo, Y, Shinohara, T, Itoh, T, Shichinohe, T, Kondo, S, Kasahara, N & Katoh, H 2002, 'High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker', International Journal of Cancer, vol. 99, no. 3, pp. 418-423. https://doi.org/10.1002/ijc.10381
Hiraoka, Kei ; Hida, Yasuhiro ; Miyamoto, Masaki ; Oshikiri, Taro ; Suzuoki, Masato ; Nakakubo, Yoshihiro ; Shinohara, Toshiya ; Itoh, Tomoo ; Shichinohe, Toshiaki ; Kondo, Satoshi ; Kasahara, Noriyuki ; Katoh, Hiroyuki. / High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. In: International Journal of Cancer. 2002 ; Vol. 99, No. 3. pp. 418-423.
@article{e6e45650481d4b529eeabc0f944ecb33,
title = "High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker",
abstract = "RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a recently identified human tumor-associated antigen expressed on various cancer cells. It is thought that tumor cells evade immune surveillance by expression of RCAS1, which induces apoptotic cell death in receptor-positive immune cells. The purpose of our study was to investigate the relation between RCAS1 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma. Immunohistochemical analysis for RCAS1 was performed on paraffin-embedded specimens of 80 patients (mean age, 62 years) who underwent surgical resection for pancreatic adenocarcinoma. Of the 80 specimens, 77 (96{\%}) were positive for RCAS1. No significant correlation was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). RCAS1 expression was very frequently observed and the survival of patients with high RCAS1 expression was significantly shorter than that of those with low expression (p = 0.0012). Multivariate analysis using the Cox regression model indicated that high RCAS1 expression was an independent prognostic factor (risk ratio, 3.090; p = 0.0090). These results suggested that RCAS1 might be a significant tumor marker for pancreatic adeno-carcinoma and an unfavorable predictor for prognosis of patients who have undergone surgical resection.",
keywords = "Immunohistochemical analysis, Pancreatic carcinoma, Prognostic factor, RCAS1, Tumor-associated antigen",
author = "Kei Hiraoka and Yasuhiro Hida and Masaki Miyamoto and Taro Oshikiri and Masato Suzuoki and Yoshihiro Nakakubo and Toshiya Shinohara and Tomoo Itoh and Toshiaki Shichinohe and Satoshi Kondo and Noriyuki Kasahara and Hiroyuki Katoh",
year = "2002",
month = "5",
day = "20",
doi = "10.1002/ijc.10381",
language = "English (US)",
volume = "99",
pages = "418--423",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker

AU - Hiraoka, Kei

AU - Hida, Yasuhiro

AU - Miyamoto, Masaki

AU - Oshikiri, Taro

AU - Suzuoki, Masato

AU - Nakakubo, Yoshihiro

AU - Shinohara, Toshiya

AU - Itoh, Tomoo

AU - Shichinohe, Toshiaki

AU - Kondo, Satoshi

AU - Kasahara, Noriyuki

AU - Katoh, Hiroyuki

PY - 2002/5/20

Y1 - 2002/5/20

N2 - RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a recently identified human tumor-associated antigen expressed on various cancer cells. It is thought that tumor cells evade immune surveillance by expression of RCAS1, which induces apoptotic cell death in receptor-positive immune cells. The purpose of our study was to investigate the relation between RCAS1 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma. Immunohistochemical analysis for RCAS1 was performed on paraffin-embedded specimens of 80 patients (mean age, 62 years) who underwent surgical resection for pancreatic adenocarcinoma. Of the 80 specimens, 77 (96%) were positive for RCAS1. No significant correlation was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). RCAS1 expression was very frequently observed and the survival of patients with high RCAS1 expression was significantly shorter than that of those with low expression (p = 0.0012). Multivariate analysis using the Cox regression model indicated that high RCAS1 expression was an independent prognostic factor (risk ratio, 3.090; p = 0.0090). These results suggested that RCAS1 might be a significant tumor marker for pancreatic adeno-carcinoma and an unfavorable predictor for prognosis of patients who have undergone surgical resection.

AB - RCAS1 (receptor-binding cancer antigen expressed on SiSo cells) is a recently identified human tumor-associated antigen expressed on various cancer cells. It is thought that tumor cells evade immune surveillance by expression of RCAS1, which induces apoptotic cell death in receptor-positive immune cells. The purpose of our study was to investigate the relation between RCAS1 expression and the clinicopathological variables and clinical outcome in patients with pancreatic adenocarcinoma. Immunohistochemical analysis for RCAS1 was performed on paraffin-embedded specimens of 80 patients (mean age, 62 years) who underwent surgical resection for pancreatic adenocarcinoma. Of the 80 specimens, 77 (96%) were positive for RCAS1. No significant correlation was found between RCAS1 expression and age, gender, depth of invasion, tumor diameter, surgical margin, lymphatic invasion, venous invasion or histopathological grading. Borderline correlations between RCAS1 expression were noted for lymph node metastasis and stage (p = 0.0608 and 0.0934, respectively). RCAS1 expression was very frequently observed and the survival of patients with high RCAS1 expression was significantly shorter than that of those with low expression (p = 0.0012). Multivariate analysis using the Cox regression model indicated that high RCAS1 expression was an independent prognostic factor (risk ratio, 3.090; p = 0.0090). These results suggested that RCAS1 might be a significant tumor marker for pancreatic adeno-carcinoma and an unfavorable predictor for prognosis of patients who have undergone surgical resection.

KW - Immunohistochemical analysis

KW - Pancreatic carcinoma

KW - Prognostic factor

KW - RCAS1

KW - Tumor-associated antigen

UR - http://www.scopus.com/inward/record.url?scp=0037140959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037140959&partnerID=8YFLogxK

U2 - 10.1002/ijc.10381

DO - 10.1002/ijc.10381

M3 - Article

C2 - 11992411

AN - SCOPUS:0037140959

VL - 99

SP - 418

EP - 423

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -